Teva Expects 180-Day Generic Exclusivity On Three Pravachol Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva expects to receive 180-day generic marketing exclusivity on three of the four dosage strengths of Bristol-Myers Squibb's Pravachol (pravastatin)